- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02611219
Deconditioning in Transplant
Effect of Increased Activity on Deconditioning in Pediatric Stem Cell Transplant Recipients: A Feasibility Study
Study Overview
Status
Conditions
Intervention / Treatment
- Other: General Health Module-Baseline Adolescent-Self Report (13-18 years)
- Other: General Health Module-Follow Up Adolescent-Self Report (13-18 years)
- Other: Demographic Data Form
- Other: SCT Daily Activity Log
- Other: The Functional Independence Measure for Children
- Other: Manual Muscle Testing
- Other: 3-Minute Step Test
- Other: HSCT Module-Follow Up Adolescent-Self Report (13-18 years)
- Other: HSCT Module-Follow Child-Self Report (5-12 years)
- Other: General Health Module-Baseline Parent Report-Adolescent (13-18 years)
- Other: General Health Module-Follow Up Parent Report-Adolescent (13-18 years)
- Other: General Health Module-Baseline Parent Report-School Age (5-12 years)
- Other: General Health Module-Follow Up Parent Report-School Age (5-12 years)
- Other: HSCT Module-Follow Up Parent Report-adolescent (13-18 years)
- Other: HSCT Module-Follow Up Parent Report-School Age (5-12 years)
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (Pediatric Patients)
- Ages 7-17 years
- Admitted to hospital for stem cell transplant
- Speaks English
Inclusion Criteria (Parents of pediatric patients)
- Parents of children ages 7-17 years
- Parents of children admitted to hospital for stem cell transplant
- Speaks English
Exclusion Criteria (Pediatric Patients) -Admitted to transplant unit for autologous stem cell transplant, donor lymphocyte infusions, mesenchymal cell infusions, a second stem cell transplant, graft versus host disease or other complications post stem cell transplant will not be included
Exclusion Criteria (Parents of pediatric patients)
-Parents of children admitted to transplant unit for autologous stem cell transplant, donor lymphocyte infusions, mesenchymal cell infusions, a second stem cell transplant, graft versus host disease or other complications post stem cell transplant will not be included
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm 1: Pediatric patients
|
-16 questions about demographics such as household income, race, and gender
Other Names:
-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length.
Using a "break" test, the test giver overpowers the muscle being tested to determine the muscle grade.
Other Names:
|
|
Experimental: Arm 2: Parents of pediatric patients
|
-16 questions about demographics such as household income, race, and gender
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment and retention of participants throughout the study
Time Frame: Baseline through 6 week clinic visit (up to an estimated 82 days)
|
-Analyze the number of participants enrolled who continue through the 6 week clinic visit
|
Baseline through 6 week clinic visit (up to an estimated 82 days)
|
|
Number of participants who achieve 6 hours out of bed through the 6 week clinic visit
Time Frame: Baseline through 6 week clinic visit (up to an estimated 82 days)
|
Baseline through 6 week clinic visit (up to an estimated 82 days)
|
|
|
Quality of life as measured by General Health Module questionnaires
Time Frame: Discharge from hospital (estimated to be 40 days)
|
Discharge from hospital (estimated to be 40 days)
|
|
|
Quality of life as measured by General Health Module questionnaires
Time Frame: Baseline through 6 week clinic visit (up to an estimated 82 days)
|
Baseline through 6 week clinic visit (up to an estimated 82 days)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Heather Taylor, RN, BSN, CPHON, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 201406031
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic and Stem Cell Transplant
-
Brigham and Women's HospitalDana-Farber Cancer Institute; Duke University; H. Lee Moffitt Cancer Center and...RecruitingHematopoietic Stem Cell TransplantUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedHematopoietic Stem Cell TransplantUnited States
-
Children's Hospital Medical Center, CincinnatiCompletedHematopoietic Stem Cell TransplantUnited States
-
The University of Hong KongRecruitingHematopoietic Stem Cell Transplant (HSCT)Hong Kong
-
Mayo ClinicNot yet recruitingHematopoietic Stem Cell TransplantUnited States
-
Children's Hospital Los AngelesCompleted
-
Children's Hospital Medical Center, CincinnatiCompletedHematopoietic Stem Cell TransplantUnited States
-
Case Comprehensive Cancer CenterCompletedHematopoietic Stem Cell TransplantUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownHematopoietic Stem Cell TransplantFrance
-
Children's Hospital Medical Center, CincinnatiCompletedHematopoietic Stem Cell TransplantUnited States